Use of the experimental therapy BDB-001 helps adults with ANCA-associated vasculitis (AAV) achieve at least partial disease remission, while…
Articles by Margarida Maia, PhD
Measuring circulating microRNAs — short RNA molecules that ultimately suppress gene activity — could offer doctors a less invasive way…
Treatment with the immunosuppressants cyclophosphamide, azathioprine, or rituximab after ANCA-associated vasculitis (AAV) patients have experienced a brain bleed, or…
In adults with ANCA-associated vasculitis (AAV), the amount of TWEAK protein in urine was about 50% as high when…
Vertex Pharmaceuticals has signed a license agreement with Ono Pharmaceutical to develop and market povetacicept — a B-cell-targeting…
Updated treatment guidelines from the British Society for Rheumatology favor rituximab over cyclophosphamide for active, relapsing ANCA-associated vasculitis…
Treatments for ANCA-associated vasculitis (AAV) have improved over time, but many patients still develop permanent organ damage, even though…
People diagnosed with ANCA-associated vasculitis (AAV) at age 75 or older may show more inflammation, higher rates of kidney…
An imaging test that can make detailed pictures of the heart can detect scar tissue buildup in the heart muscle…
Infections are a leading cause of early death in adults with ANCA-associated vasculitis (AAV), being most common in the…